Should I buy or sell Spruce Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRB, but not buy additional shares or sell existing shares. View SPRB analyst ratings or view top-rated stocks .

What is Spruce Biosciences' stock price target for 2024?

8 Wall Street analysts have issued twelve-month price targets for Spruce Biosciences' stock. Their SPRB share price targets range from $2.00 to $10.00. On average, they expect the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 709.1% from the stock's current price. View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts .

How have SPRB shares performed in 2024?

Spruce Biosciences' stock was trading at $2.93 at the beginning of the year. Since then, SPRB shares have decreased by 76.1% and is now trading at $0.7004. View the best growth stocks for 2024 here .

Are investors shorting Spruce Biosciences?

Spruce Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 320,400 shares, an increase of 69.3% from the March 15th total of 189,300 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 0.3 days. Approximately 1.5% of the company's shares are sold short. View Spruce Biosciences' Short Interest .

When is Spruce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SPRB earnings forecast .

How were Spruce Biosciences' earnings last quarter?

Spruce Biosciences, Inc. (NASDAQ:SPRB) issued its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.18. The company earned $2.89 million during the quarter, compared to the consensus estimate of $1.65 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 52.31% and a negative net margin of 474.96%.

When did Spruce Biosciences IPO?

Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of Spruce Biosciences?

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free SPRB Stock Alerts

$0.70

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.69
▼
$0.71
50-Day Range: $0.70
▼
$5.49
52-Week Range: $0.68
▼
$5.95

Volume: 627,672 shs
Average Volume: 1.13 million shs
Market Capitalization: $28.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Get Spruce Biosciences alerts:

Spruce Biosciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 709.1% Upside
$5.67 Price Target
Short Interest: Healthy
1.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.33) to ($1.16) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

406th out of 911 stocks

Pharmaceutical Preparations Industry

179th out of 411 stocks

4.1

Analyst's Opinion

Consensus Rating
Spruce Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Spruce Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.46% of the float of Spruce Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Spruce Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Spruce Biosciences has recently increased by 69.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Spruce Biosciences does not currently pay a dividend.
Dividend Growth
Spruce Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRB.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spruce Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,613,101.00 in company stock.
Percentage Held by Insiders
Only 9.10% of the stock of Spruce Biosciences is held by insiders.
Percentage Held by Institutions
91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Spruce Biosciences are expected to grow in the coming year, from ($1.33) to ($1.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spruce Biosciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spruce Biosciences is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Spruce Biosciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Spruce Biosciences Stock (NASDAQ:SPRB)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

SPRB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SPRB Stock News Headlines

March 22, 2024 | insidertrades.com

Holdings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock

March 19, 2024 | insidertrades.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Major Shareholder Holdings A/S Novo Sells 1,912,316 Shares

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

March 27, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

March 23, 2024 | finance.yahoo.com

Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

March 16, 2024 | finance.yahoo.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 14, 2024 | marketwatch.com

Spruce Biosciences Shares Dive 74% After Terminating Genetic Disease Study, Cutting Staff

March 14, 2024 | markets.businessinsider.com

Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall

March 14, 2024 | businesswire.com

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

March 14, 2024 | marketwatch.com

Stocks to Watch: Spruce Biosciences, UiPath

March 14, 2024 | markets.businessinsider.com

Spruce Biosciences FY23 Loss Widens, CAHmelia-203 Study Fails; Stock Down In Pre-market

March 14, 2024 | msn.com

Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?

March 14, 2024 | investorplace.com

Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose Cohorts

March 13, 2024 | msn.com

Spruce Biosciences stock craters 75% on failed Phase 2 study

March 13, 2024 | finance.yahoo.com

Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks

March 13, 2024 | businesswire.com

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

March 13, 2024 | businesswire.com

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

February 23, 2024 | benzinga.com

Spruce Biosciences Stock (NASDAQ:SPRB), Short Interest Report

February 21, 2024 | msn.com

Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts

February 21, 2024 | msn.com

Guggenheim Initiates Coverage of Spruce Biosciences (SPRB) with Buy Recommendation

January 30, 2024 | finance.yahoo.com

Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 22, 2024 | finance.yahoo.com

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

January 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Spruce Biosciences Amid Positive Clinical Trials and Market Potential for Tildacerfont

See More Headlines

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SPRB
CUSIP: N/A
CIK: 1683553
Web: www.sprucebiosciences.com
Phone: 415-655-4168
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $10.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +709.5%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,920,000.00
Net Margins: -474.96%
Pretax Margin: -474.96%
Return on Equity: -52.31%
Return on Assets: -39.77%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 4.18
Quick Ratio: 4.18

Sales & Book Value

Annual Sales: $10.09 million
Price / Sales: 2.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.88 per share
Price / Book: 0.37

Miscellaneous

Outstanding Shares: 41,150,000
Free Float: 37,408,000
Market Cap: $28.81 million
Optionable: Optionable
Beta: 2.52

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Michael G. Grey (Age 71)
Executive Chairman
Comp: $70k
Dr. Javier Szwarcberg M.D. (Age 54)
M.P.H., CEO & Director
Comp: $693.9k
Mr. Samir M. Gharib CPA (Age 42)
M.B.A., President & CFO
Comp: $536.13k
Dr. Ralph William Charlton III (Age 54)
M.D., Chief Medical Officer
Comp: $436.38k
Ms. P. J. Ramtin
Senior Vice President of Business Operations
Ms. Heidi Petersen M.P.H.
Senior Vice President of Regulatory & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPRB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRB, but not buy additional shares or sell existing shares.
View SPRB analyst ratings or view top-rated stocks.
What is Spruce Biosciences' stock price target for 2024?: 8 Wall Street analysts have issued twelve-month price targets for Spruce Biosciences' stock. Their SPRB share price targets range from $2.00 to $10.00. On average, they expect the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 709.1% from the stock's current price.
View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts.
How have SPRB shares performed in 2024?: Spruce Biosciences' stock was trading at $2.93 at the beginning of the year. Since then, SPRB shares have decreased by 76.1% and is now trading at $0.7004.
View the best growth stocks for 2024 here.
Are investors shorting Spruce Biosciences?: Spruce Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 320,400 shares, an increase of 69.3% from the March 15th total of 189,300 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 0.3 days. Approximately 1.5% of the company's shares are sold short.
View Spruce Biosciences' Short Interest.

When is Spruce Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SPRB earnings forecast.
How were Spruce Biosciences' earnings last quarter?: Spruce Biosciences, Inc. (NASDAQ:SPRB) issued its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.18. The company earned $2.89 million during the quarter, compared to the consensus estimate of $1.65 million. Spruce Biosciences had a negative trailing twelve-month return on equity of 52.31% and a negative net margin of 474.96%.
When did Spruce Biosciences IPO?: Spruce Biosciences (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO.
How do I buy shares of Spruce Biosciences?: Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Spruce Biosciences (SPRB) Stock Price, News & Analysis

Spruce Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Spruce Biosciences Stock (NASDAQ:SPRB)

SPRB Stock Price History

SPRB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SPRB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™